Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol...
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
JERSEY CITY, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to...
MINNEAPOLIS, MN, US, Aug. 28, 2023 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company"), an emerging...
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the...
New preclinical data characterizing NE3107 mechanism of action featured in oral presentationPhamacokinetic data from Phase 2a study supports potential co-administration...
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel...
STOUGHTON, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed...
WAKEFIELD, MA, Aug. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical...
ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an...
Bionano original equipment manufacturing (OEM) partner A-smart MedTech (A-smart) obtained reagent class I registration and approval for DNA isolation and...
The LIGHTHOUSE study evaluating the safety and tolerability of investigational gene therapy ATSN-201 is enrolling male patients ages 6-64 with...
Financing led by RA Capital Management with participation from Insight Partners, NVIDIA, and Gaingels Superluminal combines deep biology and chemistry...
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical...
Companies to explore collaboration opportunities within LEXEO’s preclinical cardiovascular pipelineNEW YORK, Aug. 28, 2023 (GLOBE NEWSWIRE) -- LEXEO Therapeutics (LEXEO),...
Phase 2b trial of TOUR006 is expected to report top-line clinical data in the first half of 2025NEW YORK, Aug....
CARLSBAD, Calif., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF),...
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations...
More than 135 patients recruited in four months for Phase 2 study of a single intravitreal (IVT) injection of ONL1204...
WATERTOWN, Mass., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...